![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CARGO Therapeutics Inc | NASDAQ:CRGX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.78 | 4.99% | 16.42 | 16.10 | 26.30 | 16.75 | 15.8975 | 15.95 | 553,615 | 21:34:18 |
TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHAGina Chapman, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat on Tuesday, May 28, at 11:00 a.m. ET.
Jefferies Global Healthcare ConferenceGina Chapman, President and Chief Executive Officer, is scheduled to participate in a fireside chat on Wednesday, June 5, at 11:30 a.m. ET, in New York City.
Interested parties can access the live webcasts for the conferences in the Investors section of CARGO’s website under News & Events. The webcast replays will be available after the conclusion of the live presentations for approximately 30 days.
About CARGO TherapeuticsCARGO Therapeutics, Inc. is a clinical-stage biotechnology company positioned to advance next- generation, potentially curative cell therapies for cancer patients. CARGO’s programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved cell therapies, including limited durability of effect, safety concerns and unreliable supply. CARGO is currently evaluating its lead program, firicabtagene autoleucel (firi-cel) (CRG-022), an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, in a potentially pivotal Phase 2 clinical study in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. CARGO also plans to evaluate firi-cel (CRG-022) in patients at earlier stages of disease, including LBCL and other hematologic malignancies. Beyond its lead program, CARGO is leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic “cargo” designed to enhance CAR T-cell persistence and trafficking to tumor lesions, as well as to help safeguard against tumor resistance and T-cell exhaustion. This includes the CRG-023 program, which incorporates a tri-specific CAR T with CD2 co-stimulation. CARGO’s founders are pioneers and world-class experts in CAR T-cell therapy, and its team has significant experience and success in developing, manufacturing, launching and commercializing oncology and cell therapy products. For more information, please visit the CARGO Therapeutics website at https://cargo-tx.com/.
Follow us on LinkedIn: CARGO TherapeuticsFollow us on X (Twitter): @CARGOTx
ContactsMedia Contact:Kimberly Muscarakimberly@redhousecomms.com
Investor Contact:Jessica Serrajserra@cargo-tx.com
Laurence Wattslaurence@newstreetir.com
1 Year CARGO Therapeutics Chart |
1 Month CARGO Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions